toxylact: a02bx02 sucralfate
The first professional lActological database in the word
Sucralfate (ATC A02BX02) is generally considered compatible with breastfeeding, with minimal systemic absorption and only theoretical risk of aluminum accumulation in women with significant renal impairment.
Pharmacological profile
Sucralfate is a basic aluminum salt of sulfated sucrose that acts as a locally active gastro-duodenal mucosal protective agent. It is indicated for short-term treatment of active duodenal ulcer and for maintenance to prevent recurrence, and is also used in gastric ulcer, GERD, gastritis and stress-ulcer prophylaxis. The drug forms a viscous paste in acidic gastric pH that selectively binds to ulcer surfaces, creating a protective barrier against acid and pepsin and promoting healing. Sucralfate is classified in ATC group A02BX02 (alimentary tract and metabolism – other antiulcer agents).
Systemic absorption of sucralfate after oral administration is very low; less than about 5% of the dose is absorbed, and most of the drug (including the aluminum complex) is eliminated unchanged in the feces. The elimination half-life of the small absorbed fraction is reported in the range of roughly 6–20 hours, but this has little clinical relevance in patients with normal renal function due to the low absorbed amount.
Toxicology and adverse effects
Sucralfate is generally well tolerated, with predominantly mild gastrointestinal adverse effects such as constipation, nausea, vomiting, diarrhea, and dry mouth, and occasional minor hypersensitivity reactions. In patients with normal renal function, clinically relevant aluminum accumulation is not expected, given the minimal absorption and predominant fecal excretion.
In patients with compromised renal function (chronic kidney disease or end-stage renal disease), aluminum accumulation and toxicity have been reported with sucralfate therapy, manifesting as osteodystrophy, osteomalacia, and encephalopathy. The toxic risk may be enhanced when sucralfate is combined with agents that increase aluminum absorption (for example, citric acid–containing preparations), and at high cumulative doses or prolonged courses. Therefore, sucralfate should be used with particular caution or avoided in severe renal impairment, and alternative non-aluminum-containing gastroprotective agents may be preferable in this setting.
Other clinical cautions mentioned in product information and expert guidance include use in patients with diabetes (due to sucrose content in some formulations), significant swallowing disorders (risk of aspiration of suspension or tablets), and known hypersensitivity to sucralfate or excipients.
Lactation safety
Most expert sources consider sucralfate acceptable during breastfeeding, and it is generally listed as compatible. Systemic absorption in the mother is minimal, so only trace amounts, if any, would be expected to reach breast milk. Given sucralfate’s poor oral bioavailability and the tiny potential exposure, the breastfed infant is very unlikely to absorb any clinically significant quantity from milk, and even gastrointestinal toxicity is not expected.
Some product monographs state that it is not known whether sucralfate is excreted in human milk and recommend caution when administering the drug to nursing women, reflecting a precautionary labeling approach rather than documented harm. LactMed and other lactation-focused resources nonetheless classify sucralfate as acceptable for use in breastfeeding, and routine interruption of breastfeeding or special timing measures are not required. In the local classification used in your project, sucralfate corresponds to a toxico-lactational category I, i.e. fully suitable for use in lactation.
When assessing risk, special attention should be given to mothers with advanced renal impairment, in whom aluminum accumulation risk is higher; in such cases, overall benefit–risk of sucralfate (not specifically lactational risk) should be reconsidered, and other options may be preferred. For healthy breastfeeding women without significant renal disease, sucralfate can be considered a first-line gastroprotective drug from a toxico-lactological perspective.
Pregnancy considerations
Sucralfate is classified as FDA pregnancy category B in older labeling systems, indicating that animal studies have not demonstrated fetal risk and that controlled human data are limited but reassuring. Clinical experience and reviews suggest sucralfate appears safe in pregnancy, and its predominantly local action with minimal systemic absorption further supports its favorable toxicological profile in pregnant patients.
Practical toxico-lactologic conclusions
From a toxico-lactologic standpoint, sucralfate (A02BX02) is a locally acting gastroprotective agent with negligible maternal systemic exposure and almost no expected transfer to breast milk, making it highly suitable for use during breastfeeding. The main toxicological concern is aluminum accumulation in women with severe renal impairment or in special settings of prolonged high-dose therapy and interacting drugs that increase aluminum absorption, where close monitoring or alternative therapy should be considered. In routine clinical practice, standard-dose sucralfate can be used in nursing mothers without dose adjustment, without timing feeds around doses, and without expected adverse effects in the infant.


